Hengrui Medicine (01276) plans to repurchase 1 to 2 billion yuan worth of A shares.

Wisdom Finance and Economics APP News, A release from Hengrui Medicine (01276) stated that, based on confidence in the company's future development prospects and fundamental judgment, in order to protect the interests of the company and the majority of investors, improve the company's long-term incentive mechanism for employees, and fully mobilize employees' enthusiasm, the company plans to repurchase A shares with its own funds. The total amount of funds planned for repurchase is not less than RMB 1 billion and not more than RMB 2 billion, with a repurchase price not exceeding RMB 90.85 per share (including). The shares repurchased this time will be used for the A stock employee shareholding plan.